Stock Comparison

ABBV vs LLY

AbbVie Inc vs Eli Lilly and Co

The Verdict

LLY takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$965.0B

104.8

P/E Ratio

52.6

5.8%

Profit Margin

N/A

95.6%

Return on Equity

N/A

20.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Moderate

0.1

DVR Score

0.5

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.